Lord, Abbett & Co
LRMR icon

Lord, Abbett & Co’s Larimar Therapeutics LRMR Stock Holding History

Lord, Abbett & Co’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-13,597
Closed -$5.21M – 922
2015
Q3 		$5.21M Sell
13,597
-878
-6% -$396K 0.02% 728
2015
Q2 		$6.01M Buy
+14,475
New +$6.06M 0.02% 741

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Lord, Abbett & Co's LRMR Position: Q4 2015 in Review

Lord, Abbett & Co sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 13,597 shares — an estimated $5.21M sold.

Lord, Abbett & Co first reported a position in LRMR in Q2 2015 and held it in 2 quarters. The position peaked at $6.01M in Q2 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Lord, Abbett & Co reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 13,597 Larimar Therapeutics shares in Q4 2015, an estimated $5.21M.
  • Lord, Abbett & Co first reported a position in Larimar Therapeutics in Q2 2015 and held it in 2 quarters.
  • Lord, Abbett & Co's Larimar Therapeutics position peaked at $6.01M in Q2 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Lord, Abbett & Co's 13F filing for Q4 2015, filed 16 Feb 2016.